FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/An overview of how adipose tissue changes with age and its implications for metabolic health, focusing on potential therapeutic strategies.
研究ライブラリに戻る

An overview of how adipose tissue changes with age and its implications for metabolic health, focusing on potential therapeutic strategies.

May 16, 2026
Share

元の論文

Adipose tissue ageing: implications for metabolic health and lifespan.

Wang Guan et al.Nature reviews. Endocrinology2025
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

The Aging Fat: How Changes in Adipose Tissue Impact Metabolic Health

Published: May 16, 2026 | Source: Nature reviews. Endocrinology (2025) | Category: Peptide Therapy and Metabolism

Overview

A new review published in Nature Reviews Endocrinology explores how adipose tissue changes as we age and its implications for metabolic health. This comprehensive analysis highlights the role of various cell types within fat tissue and potential therapeutic strategies to mitigate age-related diseases.

Study Background

Until recently, little attention was paid to the aging process of adipose tissue despite its crucial role in energy homeostasis and insulin sensitivity. Researchers aimed to fill this gap by summarizing existing literature on how different types of adipose tissue change over time and their impact on metabolic health and lifespan.

What the Research Found

The review details significant changes in white and thermogenic fat tissues as we age, affecting cell types such as adipocytes (fat cells), immune cells, and senescent cells. These changes can lead to conditions like fatty liver disease and cardiovascular diseases. The study also highlights potential interventions, including caloric restriction, metformin, GLP-1 receptor agonists, and senolytics, which may help mitigate these age-related issues.

What This Means for Peptide Users

For those using peptides or considering them as part of a health regimen, understanding how adipose tissue changes with age is crucial. While the review does not focus on peptide therapy specifically, it underscores the importance of metabolic health and suggests potential pathways that could be targeted by future peptide-based interventions.

Limitations and Caveats

As this paper is a review and not an experimental study, it synthesizes existing literature without presenting new data. This means some recent developments or specific nuances in adipose tissue research might not be fully captured. Additionally, while the suggested interventions show promise, their efficacy and safety need further investigation.

How This Compares to Previous Research

This review builds on previous studies that have identified changes in adipose tissue with aging but provides a more comprehensive analysis by integrating findings from various cell types within fat tissues. It also offers an updated perspective on potential therapeutic strategies that could be beneficial for metabolic health and longevity.

Our Analysis

PeptideVault views this review as a valuable resource for understanding the complex interplay between adipose tissue changes and age-related diseases. The authors effectively summarize current knowledge while identifying gaps in research, which can guide future studies. However, the lack of new experimental data means that some aspects of the findings remain speculative.

Key Takeaways

  • Adipose Tissue Remodeling: Adipose tissue undergoes significant changes as we age, impacting metabolic health and disease risk.
  • Cellular Changes: Various cell types within adipose tissue are affected by aging, influencing overall fat function and systemic metabolism.
  • Potential Interventions: Caloric restriction, metformin, GLP-1 receptor agonists, and senolytics show promise in mitigating age-related metabolic issues.

Original Source

Citation: Wang Guan, Song Anying, Wang Qiong A (2025). Adipose tissue ageing: implications for metabolic health and lifespan.. Nature reviews. Endocrinology. DOI: 10.1038/s41574-025-01142-8

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。